Transcript Document

CANCER AUTOVACCINE (CAV)
New specific active anticancer agent
From Science To Business
11-12 October 2006, Kyiv
G.P.Potebnya
Telephone : 259-91-94; 259-08-75
E-mail : [email protected]
R.E.Kavetsky Institute of Experimental Pathology, Oncology and
Radiobiology, NAS of Ukraine
Kyiv 03022, Ukraine
1
Proprietary information statement
 The technology material presented in this
talk is available for licensing or joint
product development.
 None of the slides contain any confidential
or proprietary information.
2
Problem Description & Market Need
Cancer Diseases (on 100 000 populations):
 In the world:
210
 Central and East Europe:
349
 Ukraine:
341(162000 in year 2005)
 Russia:
314
CAV could be used for treatment 125000 of
all cases of cancers in Ukraine.
3
Brief technology description
prof. D.G.Zatula
 CAV prepared from autologous tumor
cells and products of synthesis of a
saprophytic microorganism B.subtilis B7025;
 CAV introduced by hypodermic
injections. The complete course consists
of 3 injections with 7 day's interval. The
revaccination will be carried out through
1 and 6 months;
 CAV prevented relapses and metastasis
after surgery treatment, increased
overall and relapse-free survival of
patients;
 CAV is recommended as independent
immunotherapeutic agent in the
postoperative period.
4
Advantages
1.
2.
3.
4.
5.
6.
•
Wide specter cancer’s forms, where CAV treatment could be
used.
CAV produced from own cells of patients, so there is no any
risk of SPID, or other’s infection diseases and it’s need no
control methods concerning alien infection agents.
CAV is most effective at the late stages of cancer.
Effectiveness of CAV treatment may be compared, or better,
then chemo- or radiotherapy, but without so characteristic for
them toxic effects.
Cost of production and treatment by CAV more lower then
chemo- or radiotherapy.
Combination to other methods of therapy:
After radical operation (early stages of disease, the absence
of metastasis) an effective utilization CAV without chemo- or
radiotherapy. If it is necessary carryings out courses of chemoor the radiotherapies immunotherapy by CAV may be started
in 18-21 days after their end.
5
EFFICACY ANTICANCER AUTOVACCINE DURING
COMPLEX THERAPY IN STOMACH CANCER
PATIENTS (Overall survival)
Stomach cancer, stage ІІІ
Operation+
Vaccine
Number of patients, %
60
Operation
50
40
30
20
10
0
5
10
years
• CAV treatment
enhanced 5-years
survival (57% versus
31%), 10-years
survival (50% versus
27%);
• CAV treatment of
stomach cancer
patients has no
analogous.
6
EFFICACY ANTICANCER AUTOVACCINE DURING
COMPLEX THERAPY IN LUNG CANCER PATIENTS
(Overall survival)
Lung cancer, stage ІІІА
Operation
+Vaccine
Number of patients,%
60
Operation
50
40
30
20
10
0
3
• CAV treatment
enhanced 5-years
survival (39% versus
10%);
• CAV treatment of lung
cancer patients has no
analogous
5
years
7
Stage of development (clinical tests if
medical) and international patents
 CAV treatment were supported by National Academy
of Science of Ukraine, Ministry of Health and
Farmcommittee of Ukraine
 It was obtained permission (certificate) for using CAV
in Ukraine’s clinics
 Now 8 clinics in country successfully use this
treatment
8
Targeted Market Segment
• CAV could be used for treatment of most
spread cancers forms
Among them:
For men:
For women:
Lung cancer 21% Breast cancer - 21%
Stomach cancer- 10% Cervical cancer - 6%
Rectum cancer6% Rectum cancer- 5%
Colon cancer5% Colon cancer - 6%
9
In comparison with existing products or methods
Summary of 5-year' s survivals patients with rectum cancer
(III stage), who were undertaken different forms of treatments
Treated patients
Surgery
Overall
survival
29,0%
Relapse-free
survival
19,6%
Surgery+ radiotherapy
42,7%
34,0%
Surgery
+Chemotherapy
Surgery
+Chemotherapy+CAV
Surgery +CAV
50,0%
30,0%
77,0%
30,0%
63,0%
38,0%
10
Competitive Matrix
In comparison with another autologous anticancer
vaccines (colon cancer –5 years survival)
Characteristics
R.E.Kavetsky
Institute National
Academy of
Sciense, Kiev,
Ukraine
Massachusetts
General Hospital,
Boston, USA
Overall
survival
78%
83%
78%
Cost
100 $
5000-30000 $
5000-30000 $
Side effects
10-20%
30-40%
Components of Tumor antigens
+cytotoxic lectin
vaccine
B.subtilis
Department of
Oncology,
University
Hospital, Antwerp,
Belgium.
70-90%
Living irradiated
Living irradiated
tumor cells+ living tumor cells+ living
BCG
BCG
11
Opportunities
1. In common work to obtain licences for
CAV treatment in EC countries, USA and
Russia
2. In common work to produce and use
CAV in this countries
12
Contact information
G.P.Potebnya
Telephone : 259-91-94; 259-08-75
E-mail : [email protected]
R.E.Kavetsky Institute of Experimental
Pathology, Oncology and Radiobiology,
National Academy of Science, Ukraine
13